Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics
暂无分享,去创建一个
Elena Papaleo | Vessela N Kristensen | Richa Batra | A. Børresen-Dale | E. Papaleo | V. Kristensen | R. Batra | I. Gromova | Å. Helland | V. Haakensen | P. Gromov | Anne-Lise Børresen-Dale | Åslaug Helland | Pavel Gromov | Irina Gromova | Jaime A Espinoza | Shakila Jabeen | Vilde Haakensen | Vera Timmermans Wielenga | Maj-Lis Møller Talman | Nils Brunner | N. Brunner | Vera Timmermans Wielenga | Maj-Lis Møller Talman | Jaime A. Espinoza | S. Jabeen | Elena Papaleo
[1] E. Gonzalez-Billalabeitia,et al. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer , 2014, Breast Cancer Research.
[2] A. Ghaderi,et al. Higher circulating levels of chemokine CXCL10 in patients with breast cancer: Evaluation of the influences of tumor stage and chemokine gene polymorphism. , 2016, Cancer biomarkers : section A of Disease markers.
[3] S. Kurtzman,et al. The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. , 2003, International journal of oncology.
[4] S. Kurtzman,et al. Cytokines in human breast cancer: IL-1alpha and IL-1beta expression. , 1999, Oncology reports.
[5] Bonnie F. Sloane,et al. Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties. , 2014, The international journal of biochemistry & cell biology.
[6] N. S. Murthy,et al. Flow Cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of Superficial Transitional cell carcinoma of bladder , 2006, Cancer Immunology, Immunotherapy.
[7] B. Fingleton,et al. Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. , 2010, American journal of respiratory and critical care medicine.
[8] Benjamin Haibe-Kains,et al. CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. , 2013, The Journal of clinical investigation.
[9] Carsten Denkert,et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[11] Yung-Hyun Choi,et al. Interleukin-5 enhances the migration and invasion of bladder cancer cells via ERK1/2-mediated MMP-9/NF-κB/AP-1 pathway: involvement of the p21WAF1 expression. , 2013, Cellular signalling.
[12] I. Andrulis,et al. Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry , 2012, Clinical Cancer Research.
[13] Therese Sørlie,et al. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer , 2007, Molecular oncology.
[14] T. Nielsen,et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] J. Bunkenborg,et al. Up‐regulated Proteins in the Fluid Bathing the Tumour Cell Microenvironment as Potential Serological Markers for Early Detection of Cancer of the Breast , 2010, Molecular oncology.
[16] John D. Storey,et al. Capturing Heterogeneity in Gene Expression Studies by Surrogate Variable Analysis , 2007, PLoS genetics.
[17] Vilppu J Tuominen,et al. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 , 2010, Breast Cancer Research.
[18] A. Orimo,et al. Emerging roles of the tumor-associated stroma in promoting tumor metastasis , 2012, Cell adhesion & migration.
[19] D. Laune,et al. Oestrogen receptor negative breast cancers exhibit high cytokine content , 2007, Breast Cancer Research.
[20] C. Shriver,et al. Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology. , 2007, Oncology reports.
[21] N. Brünner,et al. Plasma and Serum Levels of Tissue Inhibitor of Metalloproteinases-1 Are Associated with Prognosis in Node-negative Breast Cancer , 2008, Molecular & Cellular Proteomics.
[22] Torsten Hothorn,et al. On the Exact Distribution of Maximally Selected Rank Statistics , 2002, Comput. Stat. Data Anal..
[23] A. Rashid,et al. Association of inflammatory and other immune markers with gallbladder cancer: Results from two independent case-control studies. , 2016, Cytokine.
[24] I. Gromova,et al. Tumor interstitial fluid - a treasure trove of cancer biomarkers. , 2013, Biochimica et biophysica acta.
[25] Jacob J. Kennedy,et al. Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. , 2011, Cancer research.
[26] Y. Tao,et al. Platelet-Derived Growth Factor Regulates Breast Cancer Progression via β-Catenin Expression , 2011, Pathobiology.
[27] U. Jeschke,et al. Determination of Interleukin-4, -5, -6, -8 and -13 in Serum of Patients with Breast Cancer Before Treatment and its Correlation to Circulating Tumor Cells. , 2016, Anticancer research.
[28] L. Coussens,et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. , 2009, Cancer cell.
[29] Yihai Cao,et al. Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis , 2013, Nature Communications.
[30] Robert A. Kurt,et al. Tumor-derived CCL5 does not contribute to breast cancer progression , 2008, Breast Cancer Research and Treatment.
[31] J. Melkko,et al. Inflammation and prognosis in colorectal cancer. , 2005, European journal of cancer.
[32] Max S Wicha,et al. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. , 2011, The Journal of clinical investigation.
[33] Rainer Muche,et al. Prediction of Nodal Involvement in Breast Cancer Based on Multiparametric Protein Analyses from Preoperative Core Needle Biopsies of the Primary Lesion , 2008, Clinical Cancer Research.
[34] G. Watkins,et al. Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer. , 2004, European journal of cancer.
[35] K. Sandelin,et al. Proteomic Characterization of the Interstitial Fluid Perfusing the Breast Tumor Microenvironment , 2004, Molecular & Cellular Proteomics.
[36] M. Weil,et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. , 2002, Cancer research.
[37] Izhak Haviv,et al. Co-evolution of tumor cells and their microenvironment. , 2009, Trends in genetics : TIG.
[38] T. Whiteside. The tumor microenvironment and its role in promoting tumor growth , 2008, Oncogene.
[39] S. Elmaghraby,et al. Importance of serum IL-18 and RANTES as markers for breast carcinoma progression. , 2005, Journal of the Egyptian National Cancer Institute.
[40] Thomas A. Wynn,et al. Type 2 cytokines: mechanisms and therapeutic strategies , 2015, Nature Reviews Immunology.
[41] B. Fingleton,et al. Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment. , 2015, Cancer research.
[42] L. Zitvogel,et al. Interleukin‐7 (IL‐7) in Colorectal Cancer: IL‐7 is Produced by Tissues from Colorectal Cancer and Promotes Preferential Expansion of Tumour Infiltrating Lymphocytes , 1997, Scandinavian journal of immunology.
[43] F. Vizoso,et al. Relationship between the Inflammatory Molecular Profile of Breast Carcinomas and Distant Metastasis Development , 2012, PloS one.
[44] M. Swartz,et al. Regulation of tumor invasion by interstitial fluid flow , 2011, Physical biology.
[45] M. Dugo,et al. Subtype‐dependent prognostic relevance of an interferon‐induced pathway metagene in node‐negative breast cancer , 2014, Molecular oncology.
[46] Z. Trajanoski,et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.
[47] D C McMillan,et al. The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer , 2014, British Journal of Cancer.
[48] M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.
[49] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[50] Wei-Qiang Gao,et al. CCL5-Mediated Th2 Immune Polarization Promotes Metastasis in Luminal Breast Cancer. , 2015, Cancer research.
[51] H. Wiig,et al. Interstitial fluid-a reflection of the tumor cell microenvironment and secretome. , 2013, Biochimica et biophysica acta.
[52] Yung-Hyun Choi,et al. Identification of Pro-Inflammatory Cytokines Associated with Muscle Invasive Bladder Cancer; The Roles of IL-5, IL-20, and IL-28A , 2012, PloS one.
[53] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[54] Vessela Kristensen,et al. Methylation profiling with a panel of cancer related genes: Association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer , 2011, Molecular oncology.
[55] Y. Bang,et al. Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer , 2015, Gastric Cancer.
[56] Carsten Denkert,et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic , 2016, Nature Reviews Clinical Oncology.
[57] M. Gasparri,et al. Tumor infiltrating lymphocytes in ovarian cancer. , 2015, Asian Pacific journal of cancer prevention : APJCP.
[58] V. Kristensen,et al. Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells , 2015, Molecular oncology.
[59] F. Wang,et al. Specific recruitment of γδ regulatory T cells in human breast cancer. , 2013, Cancer research.
[60] Lisa M. Coussens,et al. The Basis of Oncoimmunology , 2016, Cell.
[61] P. Grambsch,et al. A Package for Survival Analysis in S , 1994 .
[62] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] G. Botti,et al. Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5 , 2016, Oncotarget.
[64] J.,et al. The New England Journal of Medicine , 2012 .
[65] L. Zitvogel,et al. Natural and therapy-induced immunosurveillance in breast cancer , 2015, Nature Medicine.
[66] Hans J. Tanke,et al. The Carcinoma–Stromal Ratio of Colon Carcinoma Is an Independent Factor for Survival Compared to Lymph Node Status and Tumor Stage , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[67] Melody A Swartz,et al. Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. , 2012, Physiological reviews.
[68] R. Gelber,et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[69] H. Wiig,et al. Tumor Interstitial Fluid Formation, Characterization, and Clinical Implications , 2015, Front. Oncol..
[70] Andrew H. Beck,et al. Systematic Analysis of Breast Cancer Morphology Uncovers Stromal Features Associated with Survival , 2011, Science Translational Medicine.
[71] R. Houot,et al. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. , 2006, European cytokine network.
[72] S. Costantini,et al. Regulatory T cells, interleukin (IL)‐6, IL‐8, Vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma , 2013, BJU international.
[73] Janna Paulsson,et al. PDGF receptors in tumor biology: prognostic and predictive potential. , 2014, Future oncology.
[74] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[75] A. Alimonti,et al. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer , 2014, Nature.
[76] Takuji Iwase,et al. Molecular characterization of apocrine carcinoma of the breast: Validation of an apocrine protein signature in a well‐defined cohort , 2009, Molecular oncology.
[77] M. Delorenzi,et al. Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.
[78] Y. Ozaki,et al. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[79] D. Venzon,et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets , 2008, The Journal of experimental medicine.
[80] K. Takatsu. Interleukin-5 and IL-5 receptor in health and diseases , 2011, Proceedings of the Japan Academy. Series B, Physical and biological sciences.
[81] S Michiels,et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.